But sad that hydroxychloroquine is still getting the short shrift, thanks to a Stalinesque campaign of erasing any mention of it.
No big profits in HCQ.
Actually HCQ is mentioned with approval in the introduction of this paper
"Receptor binding domains (RBD) of the viral spike play a critical role in SARS‐CoV‐2 and ACE2 fusion, so this is a very relevant target complex for viral inhibition.[ 16 ] As described above, various therapeutic strategies have been suggested to inhibit this interaction. Among some of the clinically tested drugs, chloroquine/hydroxychloroquine, arbidol, ribavirin, pensiclovir, favipiravir, nafamostat, nitazoxanide, and camostat mesylate have been shown to decrease virus–host cell binding or cellular internalization or release.